Evommune, Inc. (EVMN)
EVMNNYSEBiotechnology: Pharmaceutical Preparations
$7.84
+0.1900 (+2.48%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $324.30m
- P/E
- –
- EPS, last 4 quarters
- $-11.03
- Dividend yield
- –
- Day range
- –
- 52-week range
- $4.94 to $33.20
- Average volume
- –
- Previous close
- $7.65
Analysts
13 coveringBuy10 buy, 3 hold, 0 sell
Targets a year out average $22.00, +180.6% from here
Earnings
next estimate $-0.8200Next report Dec 10, 2026
Sep 2025
-22.6%
Dec 2025
-74.4%
Mar 2026
+22.9%
Jun 2026
-30.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $10.00m | – | – | – |
| Gross profit | $10.00m | – | – | – |
| Operating income | -$13.33m | -$29.72m | -$23.95m | -$34.90m |
| Net income | -$12.47m | -$28.27m | -$21.67m | -$32.25m |
News
8 latest- Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund DevelopmentMarketBeat · 4 days ago
- Evommune Consensus Price Target Decreased by 13.25% to $24.48Fintel · Sep 15, 2026
- Evommune Becomes Oversold (EVMN)BNK Invest · Jul 13, 2026
- Thursday 7/9 Insider Buying Report: LRMR, EVMNBNK Invest · Jul 9, 2026
- EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary GoalZacks · Jun 30, 2026
- Evommune's Phase 2b Trial Of EVO756 Fails To Meet Primary Endpoint, Stock Falls RTTNews · Jun 29, 2026
- Clear Street Initiates Coverage of Evommune (EVMN) with Buy RecommendationFintel · Mar 18, 2026
- 1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next DecadeThe Motley Fool · Mar 10, 2026
The company
Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company's mission is to improve patients' daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- Region
- North America
- Website
- evommune.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.